8-K: Aquestive Therapeutics Advances Anaphylm, Secures Funding

Aquestive Therapeutics provides a Q3 2025 update, highlighting Anaphylm's regulatory progress, pipeline expansion, and a strengthened balance sheet with $160 million in new financing.

Summary

• The FDA has confirmed it will not require an Advisory Committee to review Aquestive Therapeutics' New Drug Application for Anaphylm (dibutepinephrine) Sublingual Film.
• The company is preparing for a U.S. launch of Anaphylm in Q1 2026, pending FDA approval, with a PDUFA action date scheduled for January 31, 2026.
• Aquestive is expanding its commercial and medical infrastructure, engaging with Health Care Professionals and advocacy groups, and working with payers to prepare for Anaphylm's launch.
• Global expansion efforts for Anaphylm include a successful meeting with Health Canada in September 2025, progressing towards a New Drug Submission, and initial meetings with the European Union for future submission preparations.
• Two new patents have been issued for Anaphylm, extending patent protection into 2037.
• For AQST-108, the company plans to open an Investigational New Drug (IND) application with the FDA in Q4 2025 and expects to initiate a clinical study for Alopecia Areata in 1H 2026.
• In August 2025, Aquestive completed an equity raise of $85 million, including participation from several large institutional healthcare investors.
• A strategic financing of $75 million was completed with RTW Investments, LP, contingent on FDA approval of Anaphylm and refinancing of existing debt.
• The company projects a cash runway into 2027, with an ending cash balance of $129.1 million in Q3 2025.
• 2025 guidance, as of November 5, 2025, includes total revenues of approximately $44-$50 million and a Non-GAAP adjusted EBITDA loss of approximately $47-$51 million.
• A recent double-blinded survey (n=35) indicated a strong preference for the film strip (25 respondents) over a nasal spray (5 respondents) for epinephrine delivery, with 5 respondents preferring both equally.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant progress on Anaphylm's regulatory path (no AdCom, PDUFA date set, patent extension), successful capital raises that extend the cash runway, and advancement of the pipeline. While an EBITDA loss is projected, the funding secured mitigates immediate financial concerns and positions the company for a major product launch.

Positives

• FDA will not require an Advisory Committee review for Anaphylm, potentially streamlining the approval process.
• Preparation for a Q1 2026 U.S. launch of Anaphylm is underway, indicating confidence in potential approval.
• Successful global expansion efforts for Anaphylm, including progress with Health Canada and initial engagement with the EU.
• Broadened patent estate for Anaphylm with two new patents extending protection until 2037, enhancing long-term commercial potential.
• Significant strengthening of the balance sheet through an $85 million equity raise and a $75 million strategic financing, extending the cash runway into 2027.
• Advancement of the AdrenaVerse platform with plans to open an IND for AQST-108 in Q4 2025 and initiate a clinical study in 1H 2026.
• Positive patient preference survey results for the film strip over nasal spray for epinephrine delivery, suggesting potential market acceptance for Anaphylm.
• Manufacturing operations continue to generate cash.

Negatives

• The company projects a Non-GAAP adjusted EBITDA loss of approximately $47-$51 million for 2025.
• The $75 million strategic financing is subject to FDA approval of Anaphylm and refinancing of existing debt, introducing conditions to the funding.

Risks

• Delays or changes to the timing, cost, and success of product development activities and clinical trials for Anaphylm, AQST-108, and other product candidates.
• Risk of delays in the regulatory approval process through the FDA for product candidates, including Anaphylm, Libervant, and AQST-108, or failure to receive FDA approval at all.
• Potential impact of a government shutdown on the FDA's ability to act on product candidate approvals.
• Risk regarding the company's ability to generate sufficient clinical data for approval, particularly concerning pharmacokinetic and pharmacodynamic (PK/PD) comparability for Anaphylm.
• The FDA may require additional clinical studies for approval of Anaphylm.
• Success of competing products, including generics, could impact market share.
• Inherent risks in commercializing a new product, including technology, financial, market, implementation risks, and regulatory limitations.
• Challenges in developing a sales and marketing capability for commercialization of product candidates.
• Risk of not having sufficient capital and cash resources, including access to debt and equity financing, to satisfy liquidity and cash requirements, fund debt payments, and support future clinical development and commercial activities.
• Obligations under the Purchase Agreement and Royalty Rights Agreement require payments from revenues, potentially impacting funding for operations and debt payments, and ability to refinance existing debt.
• Manufacturing capabilities may not be sufficient to support demand if products are approved.
• Eroding market share for Suboxone, a sunsetting product that accounts for a substantial part of current operating revenue.
• Risk of default on debt instruments.
• Risks related to outsourcing certain sales, marketing, and other operational functions to third parties.
• Uncertainty regarding the rate and degree of market acceptance for Libervant, Anaphylm, AQST-108, and other product candidates.
• Risks associated with intellectual property rights and infringement claims, and the timely issuance or sufficiency of patent applications.
• Risk of legislation and regulatory actions affecting the business, including product pricing, reimbursement, or access.
• Risks related to claims and legal proceedings, including patent infringement, securities, business torts, investigative, product safety or efficacy, and antitrust litigation matters.
• Risks of product recalls and withdrawals.
• Risks related to disruptions in information technology networks and systems, including cybersecurity attacks.
• General economic, political (including the Ukraine and Israel wars), business, industry, regulatory, financial, and market conditions.

Future Outlook

Aquestive Therapeutics anticipates a U.S. launch for Anaphylm in Q1 2026, pending FDA approval by the January 31, 2026 PDUFA date. The company expects to open an IND for AQST-108 in Q4 2025 and initiate a clinical study in 1H 2026. With recent capital raises, the company projects a cash runway extending into 2027. For 2025, total revenues are expected to be between $44-$50 million, with a Non-GAAP adjusted EBITDA loss of $47-$51 million.

Management Comments

• The company is committed to developing new product candidates from the AdrenaVerse platform, as evidenced by strengthened clinical leadership.

Industry Context

The pharmaceutical industry continues to see innovation in drug delivery, particularly for acute conditions like anaphylaxis where rapid and convenient administration is critical. Aquestive's Anaphylm, if approved, could disrupt the market dominated by epinephrine auto-injectors by offering a needle-free, oral film alternative. The focus on expanding the AdrenaVerse platform with AQST-108 for alopecia areata also aligns with the growing market for dermatological and specialty treatments. The successful capital raises demonstrate investor confidence in the company's pipeline and commercialization strategy, especially for Anaphylm, which addresses a significant unmet need for a discreet and easy-to-use epinephrine option.

Comparison to Industry Standards

• The development of Anaphylm as an oral film for anaphylaxis positions Aquestive against established epinephrine auto-injector manufacturers like EpiPen (Viatris) and Auvi-Q (Kaléo). Anaphylm's potential as the first and only oral administration of epinephrine, if approved, would represent a significant advancement over current intramuscular injection standards of care, potentially improving patient adherence and reducing anxiety associated with needles.
• The patient preference survey results, showing 25 out of 35 respondents preferred the film strip over a nasal spray, suggest a strong potential for market acceptance compared to other non-injectable alternatives that may be in development or on the market for other indications.
• The extension of patent protection for Anaphylm into 2037 provides a competitive advantage, comparable to the long patent lives sought by leading pharmaceutical companies for their blockbuster drugs, ensuring market exclusivity for a significant period post-launch.

Stakeholder Impact

• Shareholders: Potential for significant value creation if Anaphylm is approved and successfully launched, though recent equity raise may cause dilution. The extended cash runway reduces near-term financing risk.
• Patients: Anaphylm offers a potentially transformative, needle-free option for severe allergic reactions, improving convenience and potentially adherence. AQST-108 could provide a new treatment for alopecia areata.
• Creditors: The strategic financing and extended cash runway improve the company's ability to meet its financial obligations, including principal payments on senior secured notes in 2026.
• Employees: Expansion of commercial and medical infrastructure suggests potential for job growth and stability, particularly in preparation for Anaphylm's launch.

Next Steps

• Continue preparing for a U.S. launch of Anaphylm in Q1 2026, if approved by FDA.
• Expand commercial and medical infrastructure for Anaphylm.
• Expand awareness of Anaphylm through engagement with Health Care Professionals and advocacy groups.
• Continue critical work with payers to raise awareness and prepare for Anaphylm's launch.
• Progress towards a New Drug Submission for Anaphylm in Canada following a successful meeting with Health Canada.
• Prepare for an EU submission for Anaphylm following initial meetings with the European Union.
• Open an Investigational New Drug (IND) application for AQST-108 with the FDA in Q4 2025.
• Initiate a clinical study for AQST-108 for Alopecia Areata in 1H 2026.
• Await PDUFA action date for Anaphylm on January 31, 2026.
• Await expected licensee-led U.K. regulatory approval for Libervant in Q1 2026.

Key Dates

Recommendation

The filing presents a compelling case for a 'buy' recommendation. The significant de-risking of Anaphylm's regulatory pathway, notably the FDA's decision not to require an Advisory Committee and a clear PDUFA date, substantially increases the probability of approval. The successful capital raises, totaling $160 million, provide a robust cash runway into 2027, alleviating immediate liquidity concerns and funding the critical commercial launch of Anaphylm. Furthermore, the expansion of the patent estate for Anaphylm into 2037 secures long-term market exclusivity. The positive patient preference data for the film delivery method suggests strong market potential. While an EBITDA loss is projected for 2025, this is typical for a pre-commercialization biotech firm investing heavily in launch preparations and pipeline development. The strategic financing, though conditional, further underscores institutional confidence. The company is well-positioned for a transformative period with a potentially disruptive product.

Keywords

Anaphylm, AQST-109, epinephrine, sublingual film, anaphylaxis, FDA approval, pharmaceuticals, biotechnology, drug development, AQST-108, AdrenaVerse, alopecia areata, Libervant, diazepam, capital raise, cash runway, patent protection